CYAD Stock Price, News & Analysis

Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced a transparency notification on December 17, 2021, revealing that Tolefi SA and related individuals have crossed the 20% voting rights threshold, now holding 18.65% as of December 8, 2021. This notification signals a downward passive crossing of the threshold by persons acting in concert, emphasizing significant shareholder concentration which could influence company governance. The total number of voting rights is reported at 24,961,981.

Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced a transparency notification regarding Tolefi SA and its affiliates crossing the 20% voting rights threshold. As of December 8, 2021, Tolefi SA holds 18.65% of the voting rights, down from the previous threshold. The notification details the individuals involved, including Serge Goblet and others, and highlights the number of voting rights before and after the transaction. The report emphasizes the company's ongoing focus on CAR T cell therapies.

Celyad Oncology announced the commencement of the KEYNOTE-B79 Phase 1b trial, evaluating CYAD-101 in combination with KEYTRUDA® for treating refractory metastatic colorectal cancer (mCRC) with microsatellite stable (MSS) disease. The first patient has been dosed, marking a significant step in assessing CYAD-101's potential. Preliminary data presented at the ASCO Gastrointestinal Cancers Symposium indicate promising results. The collaboration with MSD aims to explore the efficacy of this combination therapy, with initial results expected next year.

Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced receipt of a transparency notification as of December 10, 2021, indicating that CFIP CLYD LLC, an affiliate of Fortress Investment Group, has crossed the 25% ownership threshold. This entity now holds 6,500,000 shares, representing 28.77% of Celyad's shares and 26.04% of voting rights as of December 8, 2021. The notification is a legal requirement following the acquisition of voting securities, affirming Fortress's significant stake in the company.

Celyad Oncology SA (CYAD) announced a transparency notification revealing that CFIP CLYD LLC, an affiliate of Fortress Investment Group, has acquired 28.77% of its shares, equating to 6,500,000 shares, as of December 8, 2021. This acquisition crossed the statutory threshold of 25%. Fortress Investment Group LLC indirectly controls CFIP CLYD LLC and has no controlling shareholder. The notification reflects substantial voting rights, now at 26.04%. This shift may impact shareholder dynamics and the overall governance of Celyad Oncology.

Celyad Oncology announced updates from its CYAD-02 and CYAD-211 clinical programs, showcasing the efficacy of its non-gene edited shRNA technology at the 63rd ASH Annual Meeting. The Phase 1 CYCLE-1 trial of CYAD-02 for r/r acute myeloid leukemia reported a favorable tolerability profile and promising initial clinical activity. In the Phase 1 IMMUNICY-1 trial of CYAD-211 for r/r multiple myeloma, early data showed good tolerability and some patients achieving partial responses. Upcoming enhancements in treatment regimens are planned to maximize clinical benefits.

Celyad Oncology SA has completed a private placement, issuing 6.5 million shares at USD 5.00 each, raising USD 32.5 million. The funds will support research and development, including clinical work on CAR T therapies CYAD-101 and CYAD-211, and advance other preclinical candidates. The shares sold are unregistered under U.S. securities laws and come with customary resale registration rights. Celyad focuses on CAR T therapies for cancer, with a growing pipeline of products.

Celyad Oncology has announced a private placement of 6,500,000 ordinary shares with Fortress Investment Group, generating gross proceeds of USD 32.5 million (approximately EUR 28.7 million). The shares will be priced at USD 5.00 each, reflecting an 18.5% premium to the 30-day volume weighted average price. Proceeds will support R&D, including CAR T candidates CYAD-101 and CYAD-211. Following the placement, Fortress will hold 28.8% of Celyad's shares. This financing is expected to fund activities into the first half of 2023.

Celyad Oncology SA (CYAD) has announced a subscription agreement with Fortress Investment Group for the private placement of 6.5 million ordinary shares, generating gross proceeds of USD 32.5 million. The shares will be offered at USD 5.00 each, an 18.5% premium over the 30-day volume weighted average price. The funds will support research and development, including clinical trials for CAR T candidates CYAD-101 and CYAD-211. Fortress will acquire 28.8% of Celyad's shares and gain certain rights, including board nominations and rights on new equity issuance.